

1 **Adaptive immunity to human coronaviruses is widespread but low in magnitude**

2

3 Hyon-Xhi Tan<sup>1\*</sup>, Wen Shi Lee<sup>1\*</sup>, Kathleen M Wragg<sup>1</sup>, Christina Nelson<sup>1</sup>, Robyn Esterbauer<sup>1</sup>,  
4 Hannah G Kelly<sup>1,2</sup>, Thakshila Amarasena<sup>1</sup>, Robert Jones<sup>3</sup>, Graham Starkey<sup>3</sup>, Bao Zhong Wang<sup>3</sup>,  
5 Osamu Yoshino<sup>3</sup>, Thomas Tiang<sup>3</sup>, M Lindsay Grayson<sup>4</sup>, Helen Opdam<sup>5,6</sup>, Rohit D’Costa<sup>7,8</sup>,  
6 Angela Vago<sup>3</sup>, The Austin Liver Transplant Perfusionist Group<sup>9</sup>, Laura K Mackay<sup>1</sup>, Claire L  
7 Gordon<sup>1,4</sup>, Adam K Wheatley<sup>1</sup>, Stephen J Kent<sup>1,2,10</sup>, Jennifer A Juno<sup>1</sup>

8

9 \*These authors contributed equally

10

11 <sup>1</sup>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty  
12 institute for Infection and Immunity, Melbourne, VIC, Australia

13 <sup>2</sup>Australian Research Council Centre for Excellence in Convergent Bio-Nano Science and  
14 Technology, University of Melbourne, Melbourne, VIC, Australia

15 <sup>3</sup>Department of Surgery, Austin Health, Heidelberg, Victoria 3084, Australia.

16 <sup>4</sup>Department of Infectious Diseases, Austin Health, Heidelberg, Victoria 3084, Australia.

17 <sup>5</sup>DonateLife, The Australian Organ and Tissue Authority, ACT 2601, Australia.

18 <sup>6</sup>Department of Intensive Care, Austin Health, Heidelberg, Victoria 3084, Australia

19 <sup>7</sup>DonateLife Victoria, Carlton, Victoria 3053, Australia

20 <sup>8</sup>Intensive Care Unit, The Royal Melbourne Hospital, Parkville 3050, Victoria, Australia

21 <sup>9</sup>The Austin Liver Transplant Perfusionist Group comprises Greg Przybylowski, Darren Pritchard,  
22 Rod Moore, Robert Balakas, Casey Asmus and Rene Batac. Austin Health Operating Suite,  
23 Heidelberg, Victoria 3084, Australia.

24 <sup>10</sup>Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred 18 Hospital  
25 and Central Clinical School, Monash University, Melbourne, VIC, Australia

26

27 Corresponding author:

28 Dr. Jennifer Juno

29 [jennifer.juno@unimelb.edu.au](mailto:jennifer.juno@unimelb.edu.au)

30 792 Elizabeth St, Melbourne VIC 3000

31 **Abstract**

32 Endemic human coronaviruses (hCoV) circulate worldwide but cause minimal mortality.  
33 Although seroconversion to hCoV is near ubiquitous during childhood, little is known about  
34 hCoV-specific T cell memory in adults. We quantified CD4 T cell and antibody responses to  
35 hCoV spike antigens in 42 SARS-CoV-2 uninfected individuals. T cell responses were  
36 widespread within conventional memory and cTFH compartments but did not correlate with IgG  
37 titres. SARS-CoV-2 cross-reactive T cells were observed in 48% of participants and correlated  
38 with HKU1 memory. hCoV-specific T cells exhibited a CCR6<sup>+</sup> central memory phenotype in the  
39 blood, but were enriched for frequency and CXCR3 expression in human lung draining lymph  
40 nodes. Overall, hCoV-specific humoral and cellular memory are independently maintained, with  
41 a shared phenotype existing among coronavirus-specific CD4 T cells. This understanding of  
42 endemic coronavirus immunity provides insight into the homeostatic maintenance of immune  
43 responses that are likely to be critical components of protection against SARS-CoV-2.

44

## 45 **Introduction**

46 In contrast to the high pathogenicity of MERS-CoV, SARS-CoV and SARS-CoV-2  
47 coronaviruses, endemic human coronaviruses (hCoV) circulate worldwide but typically cause  
48 common colds with only limited morbidity and mortality<sup>1</sup>. Endemic hCoV encompass two alpha-  
49 coronaviruses ( $\alpha$ CoV), NL63 and 229E, and two beta-coronaviruses ( $\beta$ CoV), HKU1 and OC43<sup>1</sup>.  
50 Sero-epidemiological studies suggest that infection and seroconversion to hCoV occurs during  
51 early childhood (typically by 4 years of age)<sup>2-4</sup>, although there are discrepant reports on the  
52 prevalence of each virus within distinct geographical cohorts<sup>2,5</sup>. Despite the early development of  
53 immunity against multiple hCoV, most adults remain susceptible to periodic reinfection<sup>6-8</sup>, with  
54 increased susceptibility among immunocompromised individuals<sup>9-11</sup>. This suggests the  
55 magnitude and/or quality of hCoV-targeted immunity in adults is insufficient for sterilizing  
56 protection but instead may limit the burden of disease to asymptomatic or mild infection<sup>8</sup>.  
57 Defining the extent of serological and/or cellular immunity required to protect individuals from  
58 reinfection or severe disease remains a key question in the SARS-CoV-2 pandemic. As  
59 neutralizing responses wane after CoV infection, it is likely that a combination of serum  
60 antibody and B cell / T cell memory provide longer-term protection from the recurrence of  
61 disease<sup>12,13</sup>. The study of hCoV-specific T and B cell memory can therefore provide a key  
62 preview into the development of durable, protective SARS-CoV-2 immunity.  
63 Characterisation of population-level immunity to hCoV can also inform our understanding of  
64 cross-reactive immune responses between high pathogenicity and endemic CoV. Studies of  
65 SARS-CoV-2-specific immunity in uninfected individuals clearly demonstrate pre-existing  
66 cross-reactive antibody<sup>14-16</sup>, B cell<sup>16</sup> and T cell responses<sup>17-22</sup>. Nevertheless, it is currently  
67 unclear what contribution, if any, cross-reactive immunity plays in modulating the response to

68 SARS-CoV-2 infection or vaccination<sup>23</sup>. Detailed analyses of cross-reactive T cells suggest the  
69 majority of such responses are dominated by CD4 T cells and directed toward non-RBD epitopes  
70 of the spike (S) protein<sup>18,21,24</sup>. To date, however, consensus regarding the origin of these cross-  
71 reactive responses is lacking, with evidence both for<sup>18</sup> and against<sup>25</sup> a major contribution from  
72 hCoV-specific memory T cells.

73 Deconvolution of cross-reactive SARS-CoV-2 responses and de novo SARS-CoV-2 immunity  
74 requires a more detailed understanding of hCoV-specific serological and cellular memory.

75 Relatively little is known about population-level T or B cell memory to hCoV in adults, despite  
76 evidence suggesting an impact of recent hCoV infection on COVID-19 severity<sup>26</sup>. Several  
77 groups find widespread but modest CD4 T cell responses to hCoV proteins, with estimates for  
78 the prevalence of memory responses ranging from 70-100% of study participants<sup>24,25,27</sup>.

79 Detection of hCoV-specific CD8 T cell responses has been less reported<sup>27</sup>, and the prevalence of  
80 cross-reactive SARS-CoV-2-specific responses in these cohorts varies substantially<sup>24,25</sup>.

81 Furthermore, data comparing hCoV-specific T or B cell responses in the circulation with the  
82 presence or absence of such responses in the respiratory tract or secondary lymphoid organs  
83 (SLO) is lacking. Studies in animal models suggest that respiratory infections can generate long-  
84 lived T cell memory in lung draining lymph nodes (LDLN)<sup>28</sup>, raising the possibility of analogous  
85 responses following hCoV infection.

86 To address these knowledge gaps, we assessed the prevalence and phenotypic characteristics of  
87 hCoV spike-specific antibody, memory T cell and memory B cell responses in a cohort of  
88 SARS-CoV-2 uninfected adults. We find that the magnitude of hCoV immunity is independent  
89 of age and is characterized by robust antibody titres, widespread CD4 T cell memory within both  
90 Tmem and cTFH populations, and an enrichment of T cell memory in LDLN. In contrast,

91 neutralizing antibody activity is relatively low and memory B cells are infrequently detected in  
92 either the circulation or LDLN. Overall, our data detail a consistent pattern of hCoV-specific  
93 immune memory in the circulation and SLO which likely co-ordinate to provide long-term  
94 protection from hCoV infection.

95 **Results**

96 *hCoV-specific antibody and CD4 T cell memory is common among adults*

97 We recruited a cohort of 42 SARS-CoV-2 uninfected adults (n=21 male, n=21 female), ranging  
98 in age from 18-67 years with no recent cold or COVID-19 symptoms (Figure 1A). Consistent  
99 with previous studies<sup>15,16</sup>, we detected baseline plasma antibody responses to one or more hCoV  
100 S antigens in all participants, with substantially lower reactivity toward SARS-CoV-2 S (herein  
101 CoV-2; Figure 1B). Plasma IgG endpoint titres for hCoV antigens ranged from 1:176 to 1:18268  
102 (median 1:1485 for HKU1, IQR 1:886.8-2045; median 1:4475 for OC43, IQR 1:2082-6979;  
103 median 1:2066 for 229E, IQR 1:1185-3789; median 1:1716 for NL63, IQR 1:1193-2731).

104

105 To determine the distribution of CD4 T cell memory responses, we stimulated PBMC with  
106 recombinant S antigens and quantified antigen-specific Tmem (CD3<sup>+</sup>CD4<sup>+</sup>CD45RA<sup>+</sup>CXCR5<sup>-</sup>)  
107 by measuring upregulation of the activation markers CD25 and OX-40 by flow cytometry (a  
108 well-established activation-induced marker (AIM) assay<sup>29-31</sup>) (Figure 1C; gating in Supplemental  
109 Figure 1). Across the cohort, 88% of individuals exhibited a memory response greater than  
110 0.01% above background<sup>32</sup> to any hCoV S antigen (Figure 1D). Interestingly, the prevalence of  
111 responses was highest to HKU1 S (86% of participants), and lowest to NL63, with only 50% of  
112 individuals exhibiting NL63 S-specific responses (Figure 1D). The magnitude of responses to  
113 hCoV S antigens ranged from undetectable to a maximum of 0.84% of the Tmem compartment  
114 (Figure 1E). Among individuals with above-background responses, median antigen-specific  
115 Tmem frequencies were highest to HKU1 (median 0.133%, IQR 0.056-0.248, n=36), followed  
116 by OC43 (median 0.106%, IQR 0.049-0.170, n=34), NL63 (median 0.093%, IQR 0.055-0.168,  
117 n=21), and 229E (median 0.080%, IQR 0.050-0.124, n=27). Similar to other cohorts<sup>17,19</sup>, we find

118 48% of participants (n=20) demonstrated cross-reactive response to CoV-2 S with a median  
119 frequency of 0.049% (IQR 0.027-0.160), despite no evidence of prior infection (Figure 1D/E). T  
120 cell responses were similar when measured using either CD25/OX-40 or CD137/OX-40<sup>19</sup> AIM  
121 assays (Supplementary Figure 2A-C). Across the cohort, there was no relationship between the  
122 total frequency of hCoV S-specific Tmem and age, or any association with gender  
123 (Supplementary Figure 3A-B).

124

125 *hCoV-specific CD4 Tmem are predominately T<sub>CM</sub> cells with a CCR6<sup>+</sup> phenotype*

126 Given divergent host receptor specificity and possible differences in tissue tropism among  
127 hCoV<sup>1</sup>, we assessed whether memory or chemokine receptor phenotypes differed among S-  
128 specific CD4 T cell populations (gating in Supplementary Figure 1B). Similar to the parental  
129 Tmem population, hCoV S-specific and CoV-2 cross-reactive CD4 T cells were predominately  
130 CD27<sup>+</sup>CCR7<sup>+</sup>, classically defined as central memory T cells (T<sub>CM</sub>; Figure 2A-B). In contrast to  
131 the bulk Tmem population, however, hCoV S-specific cells were substantially enriched for  
132 CCR6 expression (with or without co-expression of CXCR3; Figure 2C-D). When comparing  
133 intra-individual responses, hCoV S-specific Tmem phenotypes were generally similar across all  
134 S antigens (Figure 2E). Prior studies have also described a dominant CCR6 phenotype of CoV-2  
135 S-specific Tmem among convalescent COVID-19 subjects<sup>33</sup>, and here we find that CoV-2 cross-  
136 reactive responses are similarly highly CCR6 biased (Figure 2D-E).

137

138 *hCoV reactivity is detected among circulating T follicular helper cell (TFH) memory*

139 Circulating TFH cells (cTFH; CXCR5<sup>+</sup>CD45RA<sup>-</sup>) comprise a clonally<sup>34</sup> and functionally<sup>29,35</sup>  
140 distinct memory CD4 T cell population identified by CXCR5 expression. Activated cTFH

141 correlate with antibody responses to infection or vaccination, and are thought to be surrogates of  
142 germinal centre (GC) TFH activity<sup>36,37</sup>. Resting cTFH, in contrast, may represent a long-lived,  
143 homeostatic memory population from which recall responses can be elicited even years after  
144 antigen exposure<sup>38-41</sup>. Like conventional Tmem, hCoV-specific and cross-reactive cTFH  
145 responses were widely detected across the cohort (Figure 3A). The frequency of donors  
146 exhibiting cTFH responses above 0.01% to each antigen was similar to that observed for Tmem  
147 responses (90% for HKU1, 88% for OC43, 69% for 229E, 59% for NL63, 43% for CoV-2).  
148 Median frequencies among responding donors were highest to HKU1 (median 0.241%, IQR  
149 0.147-0.531), followed by OC43 (median 0.213%, IQR 0.126-0.424), 229E (median 0.126%,  
150 IQR 0.061-0.340), NL63 (median 0.096%, IQR 0.050-0.210) and CoV-2 (median 0.085%, IQR  
151 0.050-0.195) (Figure 3A).  
152 Interestingly, hCoV responses comprised a greater proportion of the cTFH population compared  
153 to the Tmem compartment in a paired analysis ( $p < 0.002$  for all hCoV antigens), with some  
154 donors exhibiting a greater than 9-fold enrichment of hCoV-specific cells in the cTFH gate (data  
155 for HKU1 shown in Figure 3B). Similar to Tmem, antigen-specific cTFH were highly enriched  
156 for a CCR6<sup>+</sup>CXCR3<sup>-</sup> phenotype (Figure 3C-D). The phenotypes of HKU1- and CoV-2-specific  
157 cTFH in SARS-CoV-2-uninfected donors are consistent with phenotypes previously described in  
158 COVID-19 convalescent subjects<sup>29</sup>. Comparison of antigen-specific cTFH and Tmem cells  
159 revealed a significant enrichment of the CCR6<sup>+</sup>CXCR3<sup>-</sup> phenotype among cTFH, including the  
160 CoV-2 cross-reactive population (Figure 3E-F). These data suggest that while hCoV memory is  
161 broadly observed among both Tmem and cTFH subsets, the frequency and phenotype of these  
162 responses are, to a degree, subset-specific.  
163



164 *CoV-2 cross-reactive T cells correlate with HKU1 T cell memory*

165 It is currently unclear whether CoV-2 cross-reactive T cell responses arise primarily from hCoV  
166 memory or reflect cross-reactivity from a broad array of antigen specificities<sup>18,25</sup>. Among the  
167 cohort, subjects with CoV-2 cross-reactive CD4 T cell responses frequently exhibited memory  
168 responses to multiple hCoVs (Figure 4A). We assessed the relationship between the frequency of  
169 CoV-2 and hCoV memory responses and found significant correlations only between  $\beta$ CoV and  
170 CoV-2 cross-reactivity ( $p=0.006$  for HKU1,  $p=0.018$  for OC43; Figure 4B). This association is  
171 consistent with a greater sequence homology among  $\beta$ CoV strains (CoV-2, HKU1 and OC43)  
172 compared to the  $\alpha$ CoV 229E and NL63<sup>42,42</sup>. Among the subset of donors with cross-reactive  
173 responses, only HKU1 memory correlated with CoV-2 cross-reactivity ( $p=0.030$ , Figure 4B).  
174 Interestingly, while almost all individuals with CoV-2 cross-reactive responses exhibited HKU1  
175 and OC43 memory, the converse was not observed. Indeed, individuals with relatively similar  
176 patterns of hCoV reactivity could exhibit notably different CoV-2 reactivity (Figure 4C). There  
177 was no significant association of demographic characteristics among individuals with or without  
178 CoV-2 cross-reactive responses, although the cross-reactive group did exhibit a greater  
179 representation of women compared to those without cross-reactivity ( $p=0.06$ , Supplemental  
180 Figure 3C-D). Given the association between HKU1 and CoV-2 T cell frequencies, we assessed  
181 whether a particular phenotype of HKU-specific Tmem was related to the presence or absence of  
182 cross-reactive responses, but found no such distinctions (Supplemental Figure 3E).

183

184 *Cellular and humoral immune memory to hCoV are maintained independently*

185 Studies of convalescent COVID-19 cohorts have demonstrated a strong correlation between  
186 SARS-CoV-2-specific cTFH, memory B cells, binding IgG and serum neutralization<sup>19,29,32</sup>, as

187 expected from a coordinated acute immune response. To assess whether such associations are  
188 maintained in long-term hCoV immunity, we explored correlations between antibody and T cell  
189 responses across the cohort. Surprisingly, there was no relationship for any antigen between  
190 plasma IgG endpoint titre and the frequency of either S-specific CD4 Tmem or cTFH ( $p > 0.05$  for  
191 all; data for HKU1 and NL63 shown in Figure 5A). To gain greater insight into the coordination  
192 of cellular and humoral hCoV memory, we undertook an in-depth interrogation of immunity to  
193 NL63, which shares use of the cellular entry receptor ACE2 with SARS-CoV and CoV-2, and  
194 therefore likely has similar tissue tropisms in vivo.

195 To assess S-specific MBC and quantify plasma neutralising activity, NL63 S-specific memory B  
196 cell (MBC) probes were generated as described previously<sup>29</sup>, and a novel NL63 pseudovirus-  
197 based neutralization assay was performed with 293T cells stably expressing hACE2 as targets.  
198 MBC specific for NL63 and CoV-2 S were detected infrequently among the cohort, particularly  
199 in comparison to the frequency of CoV-2 S-specific MBC previously reported among COVID-19  
200 convalescent donors<sup>29</sup> (Figure 5B). Accordingly, the frequency of NL63 S-specific MBC did not  
201 correlate with plasma NL63 binding IgG titres (Figure 5C). Plasma neutralising activity against  
202 NL63 pseudovirus was detected among all donors tested, with a median  $IC_{50}$  of 100.7 ( $n=12$ ,  
203 IQR 56.6-234.6). Neutralising activity strongly correlated with NL63 S-specific antibody titres  
204 ( $p=0.006$ ) but was not associated with NL63 S-specific MBC frequencies (Figure 5D). We did,  
205 however, observe a trend toward a positive correlation of neutralization with NL63 S-specific  
206 cTFH responses ( $p=0.081$ ; Figure 5E). Given our prior observation that  $CCR6^+$  CoV-2 S-  
207 specific cTFH responses were inversely associated with neutralizing antibodies after COVID-  
208 19<sup>29</sup>, we assessed the correlation between NL63 neutralising activity and NL63 S-specific cTFH  
209 phenotype (for donors with NL63 S-specific cTFH responses,  $n=7$ ). Interestingly, the frequency

210 of CCR6<sup>+</sup> cTFH again negatively correlated with plasma neutralization activity (p=0.048; Figure  
211 5E), although the small sample size is a caveat of this analysis.

212

### 213 *Enrichment of HKU1 and NL63 S-specific T cells in lung-draining lymph nodes*

214 Although assessment of hCoV immunity has been primarily limited to peripheral blood, studies  
215 suggest that repeated infections with respiratory viruses can seed long-lived memory T cell  
216 responses in lung and lung-draining lymph nodes (LDLN)<sup>28,43,28,43</sup>. We therefore assessed the  
217 frequency of HKU1, NL63 and CoV-2 S-specific CD4 T cell responses in matched LDLN (n=5)  
218 and lung samples (n=6) from a human tissue biobank (gating in Supplementary Figure 5). We  
219 detected robust HKU1 and NL63 responses within the CD45RA<sup>-</sup> CD4 T cell population of  
220 LDLN (Figure 6A). Given the higher levels of background T cell activation in SLO compared to  
221 peripheral blood, we validated the specificity of the hCoV responses by confirming that antigen  
222 stimulation also drove expression of CD154 on OX-40<sup>+</sup> cells (Figure 6A). Among the 5 donors  
223 studied, the median frequency of HKU1 and NL63 S-specific Tmem was 1.2% (range 0.12-2.19)  
224 and 1.12% (range 0.31-4.04), respectively (Figure 6B). Reactivity to CoV-2 S was substantially  
225 lower, with a median of 0.07% (range 0.01-0.99). Similar antigen-specific responses were  
226 observed within the CD4<sup>+</sup>CD45RA<sup>-</sup>CXCR5<sup>+</sup> population (Figure 6B). There was limited to no  
227 evidence of ongoing hCoV S-specific GC TFH activity among the samples (data not shown).  
228 In contrast to the high frequencies of hCoV-specific CD4 T cells in LDLN, we found only  
229 modest hCoV reactivity among lung-derived CD4 T cells (Supplementary Figure 6A-B). These  
230 data are consistent with reports that tissue resident T cells (T<sub>RM</sub>) in the lung are relatively short-  
231 lived compared to other tissues<sup>44</sup>. Furthermore, the majority of AIM<sup>+</sup> cells did not exhibit a  
232 CD69<sup>+</sup>CD103<sup>+</sup> phenotype, suggesting they are unlikely to represent bona fide lung-resident T

233 cells<sup>45</sup> (Supplementary Figure 6C). Similarly, we found little evidence for the presence of NL63  
234 or CoV-2 cross-reactive MBC in either the LDLN or lung tissues (Supplementary Figure 6D-E).  
235  
236 It has been speculated that the dominant CCR6<sup>+</sup> phenotype of CoV-2-specific CD4 T cells may  
237 reflect preferential homing of these cells to the lung<sup>32,32</sup>. We therefore compared the  
238 CCR6/CXCR3 phenotypes of hCoV-specific T cells in LDLN to the peripheral blood obtained  
239 from the unmatched healthy adult cohort presented in Figures 2-3. After adjustment for baseline  
240 activation, we found that LDLN-derived hCoV S-specific Tmem exhibited a predominately  
241 CXCR3<sup>+</sup> phenotype, with a substantial population of CCR6<sup>-</sup>CXCR3<sup>+</sup> cells (median 37.7% for  
242 HKU1, 37.5% for NL63; Figure 6C-D). In contrast, only 10.8% and 11.2% of circulating HKU1  
243 and NL63 S-specific Tmem among the blood donor cohort were CCR6<sup>-</sup>CXCR3<sup>+</sup> (Figure 2D). As  
244 we previously observed for cTFH in the periphery, CXCR5<sup>+</sup> hCoV-specific T cells in the LDLN  
245 remained more likely to express CCR6 than their Tmem counterparts (Figure 6E-F).  
246 Nevertheless, LDLN-derived hCoV-specific CXCR5<sup>+</sup> cells were enriched for CXCR3 expression  
247 (median 30.7% CCR6<sup>-</sup>CXCR3<sup>+</sup> for HKU1, 19.4% for NL63) compared to the phenotypes  
248 observed among peripheral cTFH (median 6.6% CCR6<sup>-</sup>CXCR3<sup>+</sup> for HKU1, 9.8% for NL63;  
249 Figure 6E-F, Figure 3D). Collectively, these data suggest either differential retention or  
250 formation of CXCR3<sup>+</sup> hCoV S-specific CD4 T cells in LDLN compared to peripheral blood.

## 251 Discussion

252 Despite periodic re-infection, most adults experience only mild or asymptomatic hCoV infection,  
253 suggesting the presence of at least partially protective immune memory. We find that, in addition  
254 to near-universal plasma antibody reactivity to hCoV, memory T cell responses to both  $\alpha$ - and  
255  $\beta$ CoV are widespread. In contrast, the relatively modest neutralization activity against NL63 and  
256 low frequencies of S-specific MBC suggest that sterilizing humoral immunity is likely absent.  
257 Instead, additive contributions of multiple arms of adaptive immunity, in particular anti-viral T  
258 cell responses, may underpin protection.

259 While several studies have quantified hCoV-specific T cell responses in adult cohorts<sup>24,25,27</sup>, it  
260 was unclear whether the different viruses would elicit phenotypically distinct Tmem or cTFH  
261 responses. Together with studies of convalescent SARS-CoV-2-specific T cell responses<sup>29,32</sup>, our  
262 data suggest that the CCR6<sup>+</sup> phenotype of circulating hCoV-specific CD4 memory cells may be  
263 broadly reflective of coronavirus infection in humans. Indeed, AIM-based assays have  
264 consistently identified a high proportion of CCR6<sup>+</sup>CXCR3<sup>-</sup> cells among SARS-CoV-2 S-specific  
265 CD4 T cells<sup>29,32</sup>, in spite of low IL-17 production following antigen stimulation<sup>22,29,32</sup>.

266 Interestingly, longitudinal follow-up of COVID-19 convalescent subjects indicated a time-  
267 dependent increase in the proportion of CCR6<sup>+</sup> S-specific cTFH<sup>33</sup>, suggesting a convergence of  
268 phenotypes between CoV-2-specific and hCoV-specific cTFH memory over time.

269 Chemokine receptor expression on CD4 T cells is often used as a surrogate of cytokine  
270 expression and Th1/Th2/Th17 function, but these receptors also regulate lymphocyte trafficking  
271 to SLO and tissues. While there was little evidence for hCoV S-specific T cell memory in the  
272 lung, both HKU1 and NL63 responses were robustly detected in LDLN. The enrichment of  
273 CXCR3<sup>+</sup> hCoV T cell responses in LDLN compared to peripheral blood suggests a potential

274 involvement of CXCR3 expression in recruitment or retention of these cells out of the  
275 circulation. These data are consistent with observations in other respiratory infections, where  
276 CXCR3 mediates lung trafficking of antigen-specific CD4 T cells<sup>46,47</sup>. Future studies will be  
277 required to address the role, if any, for these cells in contributing to protection from re-exposure  
278 to CoV infection.

279 Consistent with other cohorts<sup>17,19</sup>, we find evidence for CoV-2 cross-reactive CD4 T cells in  
280 uninfected donors. In vitro expansion of CoV-2 cross-reactive T cell clones has demonstrated the  
281 potential for shared specificity with all hCoV<sup>18,24</sup>. However at a cohort-wide level, we find the  
282 frequency of CoV-2 cross-reactive cells correlates most strongly with HKU1 memory, although  
283 no immediate immunological or demographic features distinguish HKU1-reactive individuals  
284 with or without cross-reactive CoV-2 responses. Larger population-based studies will be required  
285 to determine any associations between particular HLA class II alleles and cross-reactive CD4  
286 responses. Although it has been speculated that pre-existing cross-reactive T cell immunity could  
287 be beneficial in the context of SARS-CoV-2 vaccines<sup>23</sup>, it should be noted that only CXCR3<sup>+</sup>,  
288 but not CCR6<sup>+</sup>, cTFH responses appear to correlate with neutralizing antibody titres during  
289 COVID-19 convalescence<sup>29,31,48</sup>. While recall of the CCR6<sup>+</sup> cTFH could induce expression of  
290 CXCR3, currently available evidence suggests the highly CCR6-biased responses to hCoV may  
291 not be beneficial in the context of vaccination or re-exposure.

292 Overall, these data clarify the characteristics of long-term immunity to endemic coronaviruses,  
293 which have comparable magnitudes and share phenotypic features of S-specific antibody and T  
294 cell memory across all four hCoV. Insight into the homeostatic maintenance of hCoV immunity  
295 is likely to provide a preview of long-term CoV-2-specific immunity established in the  
296 population after vaccination or wide-spread infection.

297

298 **Methods**

299 *Subject recruitment and sample collection*

300 SARS-CoV-2 uninfected controls were recruited as part of a previous COVID-19 study<sup>29</sup>, and  
301 relevant demographic characteristics are indicated in Figure 1A. For all participants, whole blood  
302 was collected with sodium heparin anticoagulant. Plasma was collected and stored at -80°C, and  
303 PBMCs were isolated via Ficoll Paque separation, cryopreserved in 10% DMSO/FCS and stored  
304 in liquid nitrogen. The study protocols and sample use were approved by the University of Melbourne  
305 Human Research Ethics Committee (#2056689) and all associated procedures were carried out in  
306 accordance with the approved guidelines. All participants provided written informed consent in  
307 accordance with the Declaration of Helsinki.

308 The use of tissue samples from human donors was approved by The University of Melbourne  
309 Human Research Ethics Committee (#1954691) and all associated procedures were carried out in  
310 accordance with approved guidelines. Tissues were collected from 6 donors: male, age 40-50, brain  
311 death; female, 30-40, brain death; male, 30-40, circulatory death; male, 50-60, brain death; female,  
312 60-70, brain death; female, 50-60, brain death. Tissues were passed through 70µM filters and  
313 homogenised into single cell suspensions, which were subsequently cryopreserved in 10% DMSO/FCS.

314

315 *Expression of coronavirus antigens*

316 A set of trimeric, pre-fusion stabilised coronavirus S proteins (HKU1, 229E, NL63, OC43,  
317 SARS-CoV-2) were generated for serological and flow cytometric assays using techniques  
318 previously described<sup>29</sup>. Genes encoding the ectodomain of SARS-CoV-2 S (NC\_045512; AA1-  
319 1209) with 6 proline stabilisation mutations and furin site removal (Hexapro<sup>49</sup>), the HKU1 S  
320 (NC\_006577; AA1-1291) and NL63 S (DQ445911.1; AA1-1291) with 2 proline stabilisation

321 mutations (S-2P), were cloned into mammalian expression vectors. Plasmids encoding S-2P  
322 versions of the ectodomains of OC43 and 229E were kindly provided by Dr Barney Graham,  
323 NIH. S proteins were expressed in Expi293 or ExpiCHO cells (ThermoFisher) using  
324 manufacturer's instructions and purified using Ni-NTA and size exclusion chromatography.  
325 Protein integrity was confirmed using SDS-PAGE.

326

### 327 *ELISA*

328 Antibody binding to recombinant S proteins was determined by ELISA as previously  
329 described<sup>29</sup>. Briefly, 96-well Maxisorp plates (Thermo Fisher) were coated overnight at 4°C with  
330 2µg/mL recombinant S, blocked with 1% FCS in PBS, and incubated with plasma dilutions for  
331 two hours at room temperature. Plates were washed, incubated with 1:20,000 dilution of HRP-  
332 anti-human IgG (Sigma) and developed using TMB substrate (Sigma). Endpoint titres were  
333 calculated as the reciprocal serum dilution giving signal 2× background using a fitted curve (4  
334 parameter log regression).

335

### 336 *Flow cytometric detection of hCoV reactive B cells*

337 Probes for delineating NL63 or SARS-CoV-2 S-specific B cells within cryopreserved human  
338 PBMC were generated by sequential addition of streptavidin-PE (ThermoFisher) or streptavidin-  
339 BV421 (BD), respectively, to trimeric S protein biotinylated using recombinant Bir-A (Avidity).  
340 Cells were stained with Aqua viability dye (ThermoFisher). PBMC, lung and lymph node cells  
341 were surface stained with the following monoclonal antibodies: CD14-BV510 (M5E2), CD3-  
342 BV510 (OKT3), CD8a-BV510 (3GA), CD16-BV510 (3G8), CD10-BV510 (HI10a), SA-BV510  
343 (BD), IgG-BV786 (G18-145), IgD-Cy7PE (IA6-2), and CD19 ECD (J3-119) (Beckman). Cells



344 were washed, fixed with 1% formaldehyde and acquired on a BD LSR Fortessa using BD FACS  
345 Diva.

346

347 *Flow cytometric detection of antigen-specific CD4 T cells*

348 Cryopreserved human PBMC were thawed and rested for four hours at 37°C. Cells were cultured  
349 in 96-well plates at  $1-2 \times 10^6$  cells/well and stimulated for 20 hours with 2 µg/mL of recombinant S  
350 protein from HKU1, NL63, 229E, OC43 or SARS-CoV-2. Selected donors were also stimulated  
351 with SEB (1 µg/mL) as a positive control. Following stimulation, cells were washed, stained  
352 with Live/dead Blue viability dye (ThermoFisher), and a cocktail of monoclonal antibodies.  
353 PBMC were surface stained with the following monoclonal antibodies: CD3 BUV395  
354 (SK7), CD45RA PeCy7 (HI100), CD20 BUV805 (2H7), CD154 APC Cy-7 (TRAP-1), CCR7  
355 Alexa Fluor 700 (150503) (BD Biosciences), CD27 BV510 (M-T271), CD4 BV605 (RPA-  
356 T4), CD8 BV650 (RPA-T8), CD25 APC (BC96), OX-40 PerCP-Cy5.5 (ACT35), CD69  
357 FITC (FN50), CD137 BV421 (4B4-1), CXCR3 PE Dazzle (G025H7), CCR6 BV786  
358 (G034E3) (Biolegend), and CXCR5 PE (MU5UBEE, ThermoFisher). Monoclonal antibody  
359 staining for lung and lymph node cells included: CD45RA PeCy7 (HI100), CD20  
360 BUV805 (2H7), CD154 APC Cy-7 (TRAP-1), EpCam BV711 (EBA-1), CD103 BUV395 (Ber-  
361 ACT8) (BD Biosciences), CD3 BV510 (SK7), CD4 BV605 (RPA-T4), CD8 BV650 (RPA-  
362 T8), CD25 APC (BC96), OX-40 PerCP-Cy5.5 (ACT35), CD69 FITC (FN50), PD-1  
363 BV421 (EH12.217), CXCR3 PE Dazzle (G025H7), CCR6 BV786 (G034E3) (Biolegend), and  
364 CXCR5 PE (MU5UBEE, ThermoFisher) Cells were washed, fixed with 1% formaldehyde and  
365 acquired on a BD LSR Fortessa using BD FACS Diva.

366

367 *NL63 pseudovirus neutralisation assay*

368 HIV-based lentivirus particles pseudotyped with S from NL63 were generated based on a  
369 previously published protocol<sup>50</sup>. Lenti-X 293T cells (TakaraBio) were co-transfected with a  
370 lentiviral backbone plasmid expressing Luciferase-IRES-ZsGreen (BEI Resources; NR-52948),  
371 helper plasmids encoding HIV Tat, Gag-Pol and Rev (BEI Resources; NR-52948) and a  
372 pseudotyping plasmid encoding native NL63 S protein (DQ445911.1). Lenti-X 293T cells were  
373 seeded in T175 flasks ( $18 \times 10^6$  cells/flask) and transfected using lipofectamine (ThermoFisher  
374 Scientific) according to manufacturer's instructions. At 6 hours after transfection, cell culture  
375 media was replaced with 36ml of fresh D10 media (DMEM with 10% FCS and 1% PSG). After  
376 another 48 hours of incubation, cell culture supernatants containing virions were clarified via  
377 centrifugation at 500g for 10 min, filtered through a 0.45 $\mu$ M PES filter and stored at -80°C.  
378 Infectivity of virions was determined by titration on 293T-ACE2 cells (BEI resources; NR-52511).

379  
380 For the NL63 pseudovirus neutralisation assay, poly-L-lysine (Sigma Aldrich) coated 96-well  
381 white plates (Interpath) were seeded with 293T-ACE2 cells (12,000 cells per well in 60 $\mu$ l). The  
382 next day, eight 2-fold serial dilutions of plasma (60 $\mu$ l) were incubated with NL63 pseudovirus  
383 (60 $\mu$ l) for 1 hour at 37°C (final plasma dilution of 1:20-1:2,560). Plasma-pseudovirus mixtures  
384 (100 $\mu$ l) were then added to 293T-ACE2 cells and incubated at 37°C for 48 hours. Plasma samples  
385 were tested in triplicate, with "virus+cells" and "virus only" controls included to represent 100%  
386 and 0% infectivity respectively. After 48 hours, all cell culture media was carefully removed from  
387 wells. Cells were lysed with 25 $\mu$ l of passive lysis buffer (Promega), incubated on an orbital shaker  
388 for 15 mins and developed with 30 $\mu$ l britelite plus luciferase reagent (Perkin Elmer).  
389 Luminescence was read using a FLUOstar Omega microplate reader (BMG Labtech). The relative  
390 light units (RLU) measured were used to calculate %neutralisation with the following formula:

391 ('Virus+cells' - 'sample') ÷ ('Virus+cells' - 'Virus only') × 100. The half maximal inhibitory  
392 concentration for plasma (IC<sub>50</sub>) was determined using four-parameter nonlinear regression in  
393 GraphPad Prism with curve fits constrained to have a minimum of 0% and maximum of 100%  
394 neutralisation.

395

### 396 *Statistics*

397 Statistical analysis was performed in GraphPad Prism v9. All T cell stimulation data is presented  
398 after background subtraction using the unstimulated control. Two group comparisons were  
399 performed using the Mann-Whitney test, or the Wilcoxon test for paired data. Correlations were  
400 performed using the Spearman test. P values were considered significant if <0.05.

401

### 402 **Acknowledgements**

403 The authors would like to thank the study participants and clinical teams for their participation in  
404 and assistance with the study. We gratefully acknowledge the generosity of the organ donor  
405 families for providing valuable tissue samples. We acknowledge the Melbourne Cytometry  
406 Program for provision of flow cytometry services. Funding for this work was provided by the  
407 Victorian Government, a Doherty Collaborative Research Award (JJ), the ARC Centre of  
408 Excellence in Convergent Bio-Nano Science and Technology (SJK), an NHMRC program grant  
409 APP1149990 (SJK), and philanthropic support from the Paul Ramsay Foundation (SJK and  
410 AKW). AKW is funded by an NHMRC Investigator grant. JAJ and SJK are funded by NHMRC  
411 fellowships.

412

413

414 **Author Contributions**

415 HXT, WSL, AKW, SJK and JAJ designed the study, analysed the results and wrote the  
416 manuscript. KMW, HXT, CN, WSL, RE, HGK, TA, AKW and JAJ performed the experiments.  
417 RJ, GS, BZW, OY, TT, MLG, HO, RD, AV, LKM, CLG facilitated collection of human tissues.  
418 All authors read, edited, and approved the manuscript.

419

420 **Figure Legends**

421 **Figure 1. hCoV and CoV-2 CD4 Tmem responses among healthy subjects.**

422 (A) Ages of the CoV-2 uninfected adult cohort participants (n=21 female, n=21 male) (B)  
423 Plasma samples were screened by ELISA for reactivity against S proteins from hCoV or CoV-2  
424 (n=42). Data are presented as the reciprocal endpoint titre. Dashed line indicates the limit of  
425 detection of the assay. (C) Representative plots of coronavirus S-specific CD4 Tmem  
426 (CD3<sup>+</sup>CD4<sup>+</sup>CXCR5<sup>-</sup>CD45RA<sup>-</sup>) from a single individual measured by OX-40 and CD25  
427 expression (control well stimulated with BSA). (D) Number of individuals with S-specific  
428 responses greater than 0.01% of total Tmem for each indicated antigen (n=42). Numbers in bars  
429 indicate the percentage of responders for each antigen. (E) Frequency of S-specific Tmem for  
430 each antigen (n=42). Lines indicate median. Values represent background subtracted responses;  
431 frequencies below 0.01% after background subtraction were assigned a value of 0.01%.

432

433 **Figure 2. Memory and Th phenotype of hCoV and cross-reactive SARS-CoV-2 CD4 Tmem**

434 **responses.** (A) Representative staining of CD27 and CCR7 on the total Tmem population (black)  
435 or HKU1 S-specific Tmem (red) in a single donor. (B) Quantification of memory phenotype  
436 among bulk Tmem (n=42), HKU1 (n=36), OC43 (n=34), 229E (n=27), NL63 (n=21) or CoV-2

437 (n=20)-specific Tmem. (C) Representative staining of CCR6 and CXCR3 on the total Tmem  
438 population (black) or HKU1 S-specific Tmem (red) in a single donor. (D) Quantification of Th  
439 phenotype among bulk Tmem (n=42), HKU1 (n=36), OC43 (n=34), 229E (n=27), NL63 (n=21)  
440 or CoV-2 (n=20)-specific Tmem. (E) Comparison of hCoV and SARS-CoV-2-specific T cell  
441 phenotype in a single donor with responses to all antigens. In all graphs, individuals were  
442 excluded if they did not exhibit a response to a particular antigen.

443

444 **Figure 3. Memory and Th phenotype of hCoV and cross-reactive CoV-2 cTFH responses.**

445 (A) Frequency of S-specific cTFH for each antigen (n=42). Lines indicate median. Values  
446 represent background subtracted responses; frequencies below 0.01% after background  
447 subtraction were assigned a value of 0.01%. Data points are segregated and coded as individuals  
448 without (closed circles, n=24) or with (open circles, n=18) CoV-2 cross-reactive responses. (B)  
449 Comparison of HKU1 S-specific T cell frequencies in Tmem or cTFH subsets. Plots indicate  
450 representative data from one donor. Graph shows compilation of responses from all donors  
451 (n=42). (C) Representative staining of CCR6 and CXCR3 on the total cTFH population (black),  
452 HKU1-specific (red) or CoV-2-specific cTFH (teal) in a single donor. (D) Quantification of Th  
453 phenotype among bulk cTFH (n=42), HKU1 (n=36), OC-43 (n=34), 229E (n=27), NL63 (n=21)  
454 or SARS-CoV-2 (n=20)-specific Tmem. (E) Representative CCR6/CXCR3 expression on bulk  
455 (black) or HKU1 S-specific (red) Tmem and cTFH. (F) Paired comparison of the frequency of  
456 CCR6<sup>+</sup>CXCR3<sup>-</sup> cells among hCoV or CoV-2 S-specific Tmem and cTFH populations among  
457 responding subjects. HKU, n=34; OC43, n=34; 229E, n=21; NL63, n=18; CoV-2, n=13.

458 Statistics assessed by Wilcoxon test. \*\*\*p<0.001, \*\*p<0.01, \*p<0.05

459

460 **Figure 4. Correlation between HKU1 and CoV-2 cross-reactive Tmem responses.**

461 (A) Frequency of S-specific Tmem for each antigen (n=42). Lines indicate median. Values  
462 represent background subtracted responses; frequencies below 0.01% after background  
463 subtraction were assigned a value of 0.01%. Data points are segregated and coded as individuals  
464 without (closed circles, n=22) or with (open circles, n=20) CoV-2 cross-reactive responses. (B)  
465 Spearman correlation between the frequency of CoV-2 and hCoV S-specific Tmem (n=42, black  
466 text). Correlation p value among individuals with CoV-2 responses >0.01% (n=20, grey dots) is  
467 shown in grey text. (C) Representative staining of two healthy donors with S-specific responses  
468 to all four hCoV antigens but differential responses to CoV-2 S.

469

470 **Figure 5. Relationship between serologic, T cell and B cell hCoV memory.** (A) Spearman

471 correlation between HKU1 or NL63 S-specific IgG and the frequency of antigen-specific Tmem  
472 or cTFH (n=42). Representative staining of IgD- B cells with NL63 or CoV-2 probes and  
473 quantification of NL63 and CoV-2 S-specific MBC (n=18). (C) Spearman correlation of NL63 S-  
474 specific MBC and plasma binding IgG titres (n=18). MBC frequency was assigned a minimum  
475 value of 0.001%. (D) Spearman correlation between plasma NL63 neutralization activity and  
476 NL63 S-specific IgG titres or MBC (n=12). (E) Spearman correlation between NL63  
477 neutralization activity and either total NL63 S-specific cTFH or the frequency of CCR6+  
478 antigen-specific cTFH.

479

480 **Figure 6. CD4 T cell hCoV memory in human lung draining lymph nodes** (A)

481 Representative staining of AIM and CD154 expression following stimulation with HKU1, NL63  
482 or CoV-2 S among lung-draining lymph node cell suspensions. (B) Frequency of hCoV or cross-

483 reactive CoV-2 responses among Tmem or CD4<sup>+</sup>CXCR5<sup>+</sup> populations (n=5). (C-E)  
484 Representative staining (C, E) and quantification (D, F) of CCR6 and CXCR3 expression on  
485 Tmem (C, D) or CXCR5<sup>+</sup> (E, F) S-specific cells (n=5).  
486


487 **References**

- 488
- 489 1 Liu, D. X., Liang, J. Q. & Fung, T. S. Human Coronavirus-229E, -OC43, -NL63, and -HKU1.  
490 *Reference Module in Life Sciences*, B978-970-912-809633-809638.821501-X, doi:10.1016/B978-  
491 0-12-809633-8.21501-X (2020).
  - 492 2 Dijkman, R. *et al.* The dominance of human coronavirus OC43 and NL63 infections in infants. *J*  
493 *Clin Virol* **53**, 135-139, doi:10.1016/j.jcv.2011.11.011 (2012).
  - 494 3 Dijkman, R. *et al.* Human coronavirus NL63 and 229E seroconversion in children. *J Clin*  
495 *Microbiol* **46**, 2368-2373, doi:10.1128/jcm.00533-08 (2008).
  - 496 4 Zhou, W., Wang, W., Wang, H., Lu, R. & Tan, W. First infection by all four non-severe acute  
497 respiratory syndrome human coronaviruses takes place during childhood. *BMC infectious*  
498 *diseases* **13**, 433, doi:10.1186/1471-2334-13-433 (2013).
  - 499 5 Severance, E. G. *et al.* Development of a nucleocapsid-based human coronavirus immunoassay  
500 and estimates of individuals exposed to coronavirus in a U.S. metropolitan population. *Clin*  
501 *Vaccine Immunol* **15**, 1805-1810, doi:10.1128/cvi.00124-08 (2008).
  - 502 6 Edridge, A. W. D. *et al.* Seasonal coronavirus protective immunity is short-lasting. *Nature*  
503 *medicine*, doi:10.1038/s41591-020-1083-1 (2020).
  - 504 7 Galanti, M. & Shaman, J. Direct Observation of Repeated Infections With Endemic  
505 Coronaviruses. *The Journal of infectious diseases*, doi:10.1093/infdis/jiaa392 (2020).
  - 506 8 Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. The time course of the immune  
507 response to experimental coronavirus infection of man. *Epidemiol Infect* **105**, 435-446,  
508 doi:10.1017/s0950268800048019 (1990).
  - 509 9 Lepiller, Q. *et al.* High incidence but low burden of coronaviruses and preferential associations  
510 between respiratory viruses. *J Clin Microbiol* **51**, 3039-3046, doi:10.1128/jcm.01078-13 (2013).
  - 511 10 Gerna, G. *et al.* Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains  
512 and their association with lower respiratory tract infections of hospitalized infants and  
513 immunocompromised patients. *Journal of medical virology* **78**, 938-949, doi:10.1002/jmv.20645  
514 (2006).
  - 515 11 Pene, F. *et al.* Coronavirus 229E-related pneumonia in immunocompromised patients. *Clinical*  
516 *infectious diseases : an official publication of the Infectious Diseases Society of America* **37**, 929-  
517 932, doi:10.1086/377612 (2003).
  - 518 12 McMahan, K. *et al.* Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*,  
519 doi:10.1038/s41586-020-03041-6 (2020).
  - 520 13 Lee, W. S. *et al.* Decay of Fc-dependent antibody functions after mild to moderate COVID-19.  
521 *medRxiv*, 2020.2012.2013.20248143, doi:10.1101/2020.12.13.20248143 (2020).
  - 522 14 Selva, K. J. *et al.* Distinct systems serology features in children, elderly and COVID patients.  
523 *medRxiv*, 2020.2005.2011.20098459, doi:10.1101/2020.05.11.20098459 (2020).
  - 524 15 Ng, K. W. *et al.* Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science*  
525 (*New York, N.Y.*), doi:10.1126/science.abe1107 (2020).
  - 526 16 Song, G. *et al.* Cross-reactive serum and memory B cell responses to spike protein in SARS-  
527 CoV-2 and endemic coronavirus infection. *bioRxiv*, 2020.2009.2022.308965,  
528 doi:10.1101/2020.09.22.308965 (2020).
  - 529 17 Braun, J. *et al.* SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.  
530 *Nature*, doi:10.1038/s41586-020-2598-9 (2020).
  - 531 18 Mateus, J. *et al.* Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.  
532 *Science (New York, N.Y.)* **370**, 89-94, doi:10.1126/science.abd3871 (2020).
  - 533 19 Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with  
534 COVID-19 Disease and Unexposed Individuals. *Cell*, doi:10.1016/j.cell.2020.05.015 (2020).
  - 535 20 Annika, N. *et al.* SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-  
536 cell recognition. *Research Square*, doi:10.21203/rs.3.rs-35331/v1 (2020).




- 537 21 Ogbe, A. *et al.* T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from  
538 cross-reactive antiviral responses. *medRxiv*, 2020.2009.2028.20202929,  
539 doi:10.1101/2020.09.28.20202929 (2020).
- 540 22 Sekine, T. *et al.* Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild  
541 COVID-19. *Cell* **183**, 158-168.e114, doi:10.1016/j.cell.2020.08.017 (2020).
- 542 23 Sette, A. & Crotty, S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. *Nature*  
543 *reviews. Immunology* **20**, 457-458, doi:10.1038/s41577-020-0389-z (2020).
- 544 24 Woldemeskel, B. A. *et al.* Healthy donor T cell responses to common cold coronaviruses and  
545 SARS-CoV-2. *The Journal of clinical investigation*, doi:10.1172/jci143120 (2020).
- 546 25 Bacher, P. *et al.* Low avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals  
547 and humans with severe COVID-19. *Immunity*, doi:10.1016/j.immuni.2020.11.016 (2020).
- 548 26 Sagar, M. *et al.* Recent endemic coronavirus infection is associated with less severe COVID-19.  
549 *The Journal of clinical investigation*, doi:10.1172/jci143380 (2020).
- 550 27 Mok, C. K. P. *et al.* T-cell responses to MERS coronavirus infection in people with occupational  
551 exposure to dromedary camels in Nigeria: an observational cohort study. *The Lancet. Infectious*  
552 *diseases*, doi:10.1016/s1473-3099(20)30599-5 (2020).
- 553 28 Stolley, J. M. *et al.* Retrograde migration supplies resident memory T cells to lung-draining LN  
554 after influenza infection. *The Journal of experimental medicine* **217**, doi:10.1084/jem.20192197  
555 (2020).
- 556 29 Juno, J. A. *et al.* Immunogenic profile of SARS-CoV-2 spike in individuals recovered from  
557 COVID-19. *medRxiv*, 2020.2005.2017.20104869, doi:10.1101/2020.05.17.20104869 (2020).
- 558 30 Dan, J. M. *et al.* A Cytokine-Independent Approach To Identify Antigen-Specific Human  
559 Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood.  
560 *Journal of immunology (Baltimore, Md. : 1950)* **197**, 983-993, doi:10.4049/jimmunol.1600318  
561 (2016).
- 562 31 Zhang, J. *et al.* Spike-specific circulating T follicular helper cell and cross-neutralizing antibody  
563 responses in COVID-19-convalescent individuals. *Nature microbiology*, doi:10.1038/s41564-  
564 020-00824-5 (2020).
- 565 32 Rydzynski Moderbacher, C. *et al.* Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute  
566 COVID-19 and Associations with Age and Disease Severity. *Cell*, doi:10.1016/j.cell.2020.09.038  
567 (2020).
- 568 33 Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for greater than six months  
569 after infection. *bioRxiv*, 2020.2011.2015.383323, doi:10.1101/2020.11.15.383323 (2020).
- 570 34 Brenna, E. *et al.* CD4(+) T Follicular Helper Cells in Human Tonsils and Blood Are Clonally  
571 Convergent but Divergent from Non-Tfh CD4(+) Cells. *Cell reports* **30**, 137-152.e135,  
572 doi:10.1016/j.celrep.2019.12.016 (2020).
- 573 35 Bentebibel, S. E. *et al.* Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody  
574 responses to influenza vaccination. *Science translational medicine* **5**, 176ra132,  
575 doi:10.1126/scitranslmed.3005191 (2013).
- 576 36 Crotty, S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. *Immunity* **50**,  
577 1132-1148, doi:10.1016/j.immuni.2019.04.011 (2019).
- 578 37 Koutsakos, M., Nguyen, T. H. O. & Kedzierska, K. With a Little Help from T Follicular Helper  
579 Friends: Humoral Immunity to Influenza Vaccination. *Journal of immunology (Baltimore, Md. :  
580 1950)* **202**, 360-367, doi:10.4049/jimmunol.1800986 (2019).
- 581 38 Locci, M. *et al.* Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly  
582 functional and correlate with broadly neutralizing HIV antibody responses. *Immunity* **39**, 758-  
583 769, doi:10.1016/j.immuni.2013.08.031 (2013).
- 584 39 Linterman, M. A. & Hill, D. L. Can follicular helper T cells be targeted to improve vaccine  
585 efficacy? *F1000Research* **5**, doi:10.12688/f1000research.7388.1 (2016).

- 586 40 Vella, L. A. *et al.* T follicular helper cells in human efferent lymph retain lymphoid  
587 characteristics. *The Journal of clinical investigation* **129**, 3185-3200, doi:10.1172/jci125628  
588 (2019).
- 589 41 Morita, R. *et al.* Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and  
590 contain specific subsets that differentially support antibody secretion. *Immunity* **34**, 108-121,  
591 doi:10.1016/j.immuni.2010.12.012 (2011).
- 592 42 Jaimes, J. A., André, N. M., Chappie, J. S., Millet, J. K. & Whittaker, G. R. Phylogenetic  
593 Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary  
594 Distinct and Proteolytically Sensitive Activation Loop. *J Mol Biol* **432**, 3309-3325,  
595 doi:10.1016/j.jmb.2020.04.009 (2020).
- 596 43 Anthony, S. M. *et al.* Lung-draining lymph-node-resident memory CD8 T cells mediate local  
597 protective immunity. *The Journal of Immunology* **202**, 198.197-198.197 (2019).
- 598 44 Slütter, B. *et al.* Dynamics of influenza-induced lung-resident memory T cells underlie waning  
599 heterosubtypic immunity. *Science immunology* **2**, doi:10.1126/sciimmunol.aag2031 (2017).
- 600 45 Oja, A. E. *et al.* Trigger-happy resident memory CD4(+) T cells inhabit the human lungs.  
601 *Mucosal immunology* **11**, 654-667, doi:10.1038/mi.2017.94 (2018).
- 602 46 Jeyanathan, M. *et al.* CXCR3 Signaling Is Required for Restricted Homing of Parenteral  
603 Tuberculosis Vaccine-Induced T Cells to Both the Lung Parenchyma and Airway. *Journal of*  
604 *immunology (Baltimore, Md. : 1950)* **199**, 2555-2569, doi:10.4049/jimmunol.1700382 (2017).
- 605 47 Kohlmeier, J. E. *et al.* CXCR3 directs antigen-specific effector CD4+ T cell migration to the lung  
606 during parainfluenza virus infection. *Journal of immunology (Baltimore, Md. : 1950)* **183**, 4378-  
607 4384, doi:10.4049/jimmunol.0902022 (2009).
- 608 48 Gong, F. *et al.* Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent  
609 individuals. *The Journal of clinical investigation*, doi:10.1172/jci141054 (2020).
- 610 49 Hsieh, C. L. *et al.* Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. *Science*  
611 *(New York, N.Y.)* **369**, 1501-1505, doi:10.1126/science.abd0826 (2020).
- 612 50 Crawford, K. H. D. *et al.* Protocol and Reagents for Pseudotyping Lentiviral Particles with  
613 SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* **12**, doi:10.3390/v12050513  
614 (2020).
- 615




**Figure 1. hCoV and CoV-2 CD4 Tmem responses among healthy subjects.**




(A) Ages of the CoV-2 uninfected adult cohort participants (n=21 female, n=21 male) (B) Plasma samples were screened by ELISA for reactivity against S proteins from hCoV or CoV-2 (n=42). Data are presented as the reciprocal endpoint titre. Dashed line indicates the limit of detection of the assay. (C) Representative plots of coronavirus S-specific CD4 Tmem (CD3<sup>+</sup>CD4<sup>+</sup>CXCR5<sup>-</sup>CD45RA<sup>-</sup>) from a single individual measured by OX-40 and CD25 expression (control well stimulated with BSA). (D) Number of individuals with S-specific responses greater than 0.01% of total Tmem for each indicated antigen (n=42). Numbers in bars indicate the percentage of responders for each antigen. (E) Frequency of S-specific Tmem for each antigen (n=42). Lines indicate median. Values represent background subtracted responses; frequencies below 0.01% after background subtraction were assigned a value of 0.01%.



**Figure 2. Memory and Th phenotype of hCoV and cross-reactive SARS-CoV-2 CD4 Tmem responses.** (A) Representative staining of CD27 and CCR7 on the total Tmem population (black) or HKU1 S-specific Tmem (red) in a single donor. (B) Quantification of memory phenotype among bulk Tmem (n=42), HKU1 (n=36), OC43 (n=34), 229E (n=27), NL63 (n=21) or CoV-2 (n=20)-specific Tmem. (C) Representative staining of CCR6 and CXCR3 on the total Tmem population (black) or HKU1 S-specific Tmem (red) in a single donor. (D) Quantification of Th phenotype among bulk Tmem (n=42), HKU1 (n=36), OC43 (n=34), 229E (n=27), NL63 (n=21) or CoV-2 (n=20)-specific Tmem. (E) Comparison of hCoV and SARS-CoV-2-specific T cell phenotype in a single donor with responses to all antigens. In all graphs, individuals were excluded if they did not exhibit a response to a particular antigen.








**Figure 3. Memory and Th phenotype of hCoV and cross-reactive CoV-2 cTFH responses.** (A) Frequency of S-specific cTFH for each antigen (n=42). Lines indicate median. Values represent background subtracted responses; frequencies below 0.01% after background subtraction were assigned a value of 0.01%. Data points are segregated and coded as individuals without (closed circles, n=24) or with (open circles, n=18) CoV-2 cross-reactive responses. (B) Comparison of HKU1 S-specific T cell frequencies in Tmem or cTFH subsets. Plots indicate representative data from one donor. Graph shows compilation of responses from all donors (n=42). (C) Representative staining of CCR6 and CXCR3 on the total cTFH population (black), HKU1-specific (red) or CoV-2-specific cTFH (teal) in a single donor. (D) Quantification of Th phenotype among bulk cTFH (n=42), HKU1 (n=36), OC-43 (n=34), 229E (n=27), NL63 (n=21) or SARS-CoV-2 (n=20)-specific Tmem. (E) Representative CCR6/CXCR3 expression on bulk (black) or HKU1 S-specific (red) Tmem and cTFH. (F) Paired comparison of the frequency of CCR6<sup>+</sup>CXCR3<sup>-</sup> cells among hCoV or CoV-2 S-specific Tmem and cTFH populations among responding subjects. HKU1, n=34; OC43, n=34; 229E, n=21; NL63, n=18; CoV-2, n=13. Statistics assessed by Wilcoxon test. \*\*\*p<0.001, \*\*p<0.01, \*p<0.05

**A****B****C**


### Figure 4. Correlation between HKU1 and CoV-2 cross-reactive Tmem responses.

(A) Frequency of S-specific Tmem for each antigen (n=42). Lines indicate median. Values represent background subtracted responses; frequencies below 0.01% after background subtraction were assigned a value of 0.01%. Data points are segregated and coded as individuals without (closed circles, n=22) or with (open circles, n=20) CoV-2 cross-reactive responses. (B) Spearman correlation between the frequency of CoV-2 and hCoV S-specific Tmem (n=42, black text). Correlation p value among individuals with CoV-2 responses >0.01% (n=20, grey dots) is shown in grey text. (C) Representative staining of two healthy donors with S-specific responses to all four hCoV antigens but differential responses to CoV-2 S.

**A****B****C****D****E**



**Figure 5. Relationship between serologic, T cell and B cell hCoV memory.** (A) Spearman correlation between HKU1 or NL63 S-specific IgG and the frequency of antigen-specific Tmem or cTFH (n=42). Representative staining of IgD<sup>-</sup> B cells with NL63 or CoV-2 probes and quantification of NL63 and CoV-2 S-specific MBC (n=18). (C) Spearman correlation of NL63 S-specific MBC and plasma binding IgG titres (n=18). MBC frequency was assigned a minimum value of 0.001%. (D) Spearman correlation between plasma NL63 neutralization activity and NL63 S-specific IgG titres or MBC (n=12). (E) Spearman correlation between NL63 neutralization activity and either total NL63 S-specific cTFH or the frequency of CCR6<sup>+</sup> antigen-specific cTFH.








**Figure 6. CD4 T cell hCoV memory in human lung draining lymph nodes (A)** Representative staining of AIM and CD154 expression following stimulation with HKU1, NL63 or CoV-2 S among lung-draining lymph node cell suspensions. (B) Frequency of hCoV or cross-reactive CoV-2 responses among Tmem or CD4<sup>+</sup>CXCR5<sup>+</sup> populations (n=5). (C-E) Representative staining (C, E) and quantification (D, F) of CCR6 and CXCR3 expression on Tmem (C, D) or CXCR5<sup>+</sup> (E, F) S-specific cells (n=5).


## Supplementary Figures

**A****B**


**Supplementary Figure 1. CD4 T cell gating strategy.** (A) Lymphocytes were identified by forward and side scatter, followed by doublet exclusion (FSC-A vs FSC-H), and gating on live cells with a consistent fluorescence profile over time. T cells were identified as CD20-CD3+, and CD4+CD8- cells were further defined as cTFH (CXCR5+CD45RA-) or Tmem (CXCR5-CD45RA-). (B) Tmem and cTFH populations were phenotyped using memory markers (CD27 vs CCR7) or chemokine receptors (CCR6 vs CXCR3).

**A****B****C**

**Supplementary Figure 2. CD4 Tmem responses measured by different AIM combinations.** (A) Comparison of AIM marker readouts (OX-40+CD25+ vs OX-40+CD137+) in a single individual for S-specific responses to all four hCoV antigens and SARS-CoV-2 S. (B) Frequency of S-specific Tmem for each antigen (n=42). Bars indicate median. Values represent background subtracted responses; frequencies below 0.01% after background subtraction were assigned a value of 0.01%. Symbols and colours indicate individual donors with SARS-CoV-2 responses >0.01% and are matched to the individuals coded in Figure 2C. (C) Comparison of SARS-CoV-2-specific Tmem CCR6 and CXCR3 phenotype based on identification by OX-40+CD25+ or OX-40+CD137+ gates.




**Supplementary Figure 3. Demographic and immunological characteristics of total hCoV and CoV-2 cross-reactive responses.** (A) Spearman correlation of age and total hCoV Tmem frequency (n=42). (B) Total hCoV frequency according to gender (n=42). (C) Age and (D) gender distribution among individuals with no (<0.01%) CoV-2 S-specific CD4 Tmem responses (n=22) or with CoV-2 responses (n=20). (E) Phenotype of HKU1-specific Tmem in individuals without (black, n=17) or with (grey, n=19) cross-reactive CoV-2 responses. Lines and error bars indicate median and interquartile range.








#### Supplementary Figure 4. Gating strategy for resolving antigen-specific B cells

Lymphocytes were identified by FSC-A vs SSC-A gating, followed by doublet exclusion (FSC-A vs FSC-H), and gating on live CD19+ B cells. Class-switched B cells were identified as IgD-, IgG+. Binding to SARS-CoV-2 or NL63 spike was assessed.



**Supplementary Figure 5. Lymph node and lung CD4 T cell gating strategy.** (A) CD4 T cells in lymph node or lung samples were identified as lymphocytes (identified by forward and side scatter, followed by doublet exclusion) with a CD20-EpCam-Live/Dead-CD3+CD8-CD4+ phenotype. (B) Memory CD4 T cell subsets in lung draining lymph nodes were identified as CD45RA-, followed by gating based on PD-1 and CXCR5 expression to identify TFH, pre-TFH and Tmem subsets. (C) In lung samples, memory CD4 T cells were identified as CD45RA-. T<sub>RM</sub> cells were identified as CD69+CD103+.

**A****B****C****D****E**

**Supplementary Figure 6. hCoV and CoV-2 T cell and B cell responses in LDLN and lung.** (A) Representative responses to HKU1, NL63 or CoV-2 S antigen stimulation among CD4<sup>+</sup>CD45RA<sup>-</sup> T cells in the lung. (B) Quantification of S-specific T cell responses (n=6 for NL63 and CoV-2, n=5 for HKU1). (C) Expression of CD69 and CD103 on total CD4<sup>+</sup>CD45RA<sup>-</sup> lung T cells (grey) versus HKU S-specific T cells (red). (D) Representative staining of NL63 and CoV-2 S-specific MBC in LDLN and lung samples. (E) Quantification of S-specific MBC among PBMC samples from the healthy adult cohort (n=18), or human tissue biobank LDLN (n=6) or lung (n=6).